Aniruddha Rajaram Chabukswar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aniruddha Rajaram Chabukswar has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Swati Changdeo Jagdale
School of Health Sciences and Technology, Department of Pharmaceutical Sciences, Dr. Vishwanath Karad MIT World Peace University, Kothrud-411038, Pune, MH, India
15 shared publications - Bhanudas Shankar Kuchekar
MAEER's Maharashtra Institute of Pharmacy, India
4 shared publications - Kunal Ganesh Raut
Department of Pharmaceutical Sciences, School of Health Sciences and Technology, Dr. Vishwanath Karad MIT WorldPeace University, Pune. 411038, India
4 shared publications - Rajesh B. Nanaware
School of Health Sciences and Technology, Department of Pharmaceutical Sciences, Dr. Vishwanath Karad MIT-World Peace University, Pune, India
4 shared publications - Pooja Tanaji Giri
Department of Pharmaceutical Sciences, School of Health Sciences and Technology, Dr. Vishwanath Karad MIT World Peace University, Pune-411038, India
3 shared publications - Prajakta V. Adsule
School of Health Sciences and Technology, Department of Pharmaceutical Sciences, Dr. Vishwanath Karad MIT World Peace University, Pune-411038, Maharashtra, India
3 shared publications
Latest Publications
- 17 August 2026
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Medicinal Chemistry
- Vol. 26, 1-17
Casein Kinase 1 and CK2 as Therapeutic Targets in Cancer: Molecular Pharmacology, Toxicological Considerations, and Clinical Progress
Casein kinase 1 (CK1) and casein kinase 2 (CK2) are highly conserved serine/threonine protein kinases that regulate multiple oncogenic signaling pathways involved in cancer progression, metastasis, and therapeutic resistance. Overexpression or dysregulation of CK1 and CK2 has been shown to contribute to the development and resistance of cancer to anticancer therapies. This review summarizes the molecular functions of CK1 and CK2 in cancer biology and evaluates the therapeutic potential, pharmacological development, and clinical progress of CK-targeted inhibitors. A structured literature search was performed using PubMed, Scopus, and Web of Science databases to identify studies published between 2000 and 2026 related to CK1/CK2 signaling, pharmacological inhibitors, toxicology, and clinical development. CK1 and CK2 are involved in the regulation of various oncogenic signaling pathways, including the Wnt/β-catenin, p53, nuclear factor kappa B, and phosphatidylinositol-3-kinase/protein kinase B signaling pathways, as well as genomic integrity pathways. Dysregulation of these kinases leads to the survival, proliferation, and resistance of cancer cells to anticancer therapies. Several CK inhibitors, including CX-4945 (Silmitasertib), CIGB- 300, IC261, D4476, SR-3029, and BTX-A51, have shown promising anticancer activity in various cancer models. Novel dual-therapy approaches targeting CK1/CK2-regulated pathways have further improved the therapeutic specificity and efficacy. CK-targeting therapies are an exciting approach and hold great promise for selectively targeting cancer-causing signaling pathways and advancing cancer precision medicine.
- 17 August 2026
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Medicinal Chemistry
- Vol. 26, 1-17
Casein Kinase 1 and CK2 as Therapeutic Targets in Cancer: Molecular Pharmacology, Toxicological Considerations, and Clinical Progress
Casein kinase 1 (CK1) and casein kinase 2 (CK2) are highly conserved serine/threonine protein kinases that regulate multiple oncogenic signaling pathways involved in cancer progression, metastasis, and therapeutic resistance. Overexpression or dysregulation of CK1 and CK2 has been shown to contribute to the development and resistance of cancer to anticancer therapies. This review summarizes the molecular functions of CK1 and CK2 in cancer biology and evaluates the therapeutic potential, pharmacological development, and clinical progress of CK-targeted inhibitors. A structured literature search was performed using PubMed, Scopus, and Web of Science databases to identify studies published between 2000 and 2026 related to CK1/CK2 signaling, pharmacological inhibitors, toxicology, and clinical development. CK1 and CK2 are involved in the regulation of various oncogenic signaling pathways, including the Wnt/β-catenin, p53, nuclear factor kappa B, and phosphatidylinositol-3-kinase/protein kinase B signaling pathways, as well as genomic integrity pathways. Dysregulation of these kinases leads to the survival, proliferation, and resistance of cancer cells to anticancer therapies. Several CK inhibitors, including CX-4945 (Silmitasertib), CIGB- 300, IC261, D4476, SR-3029, and BTX-A51, have shown promising anticancer activity in various cancer models. Novel dual-therapy approaches targeting CK1/CK2-regulated pathways have further improved the therapeutic specificity and efficacy. CK-targeting therapies are an exciting approach and hold great promise for selectively targeting cancer-causing signaling pathways and advancing cancer precision medicine.
- Open Access
- 22 July 2026
- Published by Elsevier in SSRN Electronic Journal
1,2-Diazaindene-5-Amine Derivatives As VEGFR-2 Inhibitors: Design, Synthesis, ADMET, Molecular Dynamics, Cytotoxicity Evaluation Against A549 Cell-Line
A new series of 1,2-diazaindene-5-amine derivatives was rationally designed, synthesized, and evaluated against lung cancer cell line to analyse their cytotoxic potential. A series of 30 Indazole molecules (Y1-Y30) were designed using VEGFR-2 kinase (PDB ID: 4AG8). Substituted benzaldehydes were treated with hydrazine hydrate to afford 5-nitro indazole which was subsequently reduced to 5-amino indazole and subjected to amide coupling using acid derivatives to obtain substituted 1,2-diazaindene-5-amine derivatives. Out of 30 indazole derivatives, 10 compounds were found to show significant interactions with VEGFR-2. Binding energies of Y3, Y16, and Y29 were observed in the range of -7.237-7.897 Kcal/Mol. MD simulation studies on the compounds Y3, Y16, and Y29 confirmed stable conformational behaviour of the compounds and protein. Cytotoxicity was evaluated using an MTT assay on A549 lung cancer cells. In-vitro cytotoxicity studies reveal that Y29 and Y16 were the most viable lead compounds, exhibiting strong cytotoxicity in A549 cell lines with IC50 of 26.85±0.92 μg and 31.66±0.98 μg, respectively. Compounds Y29 and Y16 were found to be the most active cytotoxic compounds against the lung A549 cell lines, which would be promising future candidates for potential lung cancer research.
- 22 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open Access1,2-Diazaindene-5-Amine Derivatives As VEGFR-2 Inhibitors: Design, Synthesis, ADMET, Molecular Dynamics, Cytotoxicity Evaluation Against A549 Cell-Line
A new series of 1,2-diazaindene-5-amine derivatives was rationally designed, synthesized, and evaluated against lung cancer cell line to analyse their cytotoxic potential. A series of 30 Indazole molecules (Y1-Y30) were designed using VEGFR-2 kinase (PDB ID: 4AG8). Substituted benzaldehydes were treated with hydrazine hydrate to afford 5-nitro indazole which was subsequently reduced to 5-amino indazole and subjected to amide coupling using acid derivatives to obtain substituted 1,2-diazaindene-5-amine derivatives. Out of 30 indazole derivatives, 10 compounds were found to show significant interactions with VEGFR-2. Binding energies of Y3, Y16, and Y29 were observed in the range of -7.237-7.897 Kcal/Mol. MD simulation studies on the compounds Y3, Y16, and Y29 confirmed stable conformational behaviour of the compounds and protein. Cytotoxicity was evaluated using an MTT assay on A549 lung cancer cells. In-vitro cytotoxicity studies reveal that Y29 and Y16 were the most viable lead compounds, exhibiting strong cytotoxicity in A549 cell lines with IC50 of 26.85±0.92 μg and 31.66±0.98 μg, respectively. Compounds Y29 and Y16 were found to be the most active cytotoxic compounds against the lung A549 cell lines, which would be promising future candidates for potential lung cancer research.
- 12 March 2026
- Published by Taylor & Francis in Journal of Receptors and Signal Transduction
- p. 1-11
Targeting vascular endothelial growth factor and its receptors in non-small cell lung cancer for improved treatment strategies
1. Angiogenesis represents one of the characteristic features of cancer and is a crucial step in the development, invasion, and metastasis of non-small cell lung cancer (NSCLC). The vascular endoth...
- 12 March 2026
- Published by Taylor & Francis in Journal of Receptors and Signal Transduction
- p. 1-11
Targeting vascular endothelial growth factor and its receptors in non-small cell lung cancer for improved treatment strategies
1. Angiogenesis represents one of the characteristic features of cancer and is a crucial step in the development, invasion, and metastasis of non-small cell lung cancer (NSCLC). The vascular endoth...
- 20 February 2026
- Published by Springer Nature in Journal of Chemical Sciences
- Vol. 138 (1) , 14
Design, synthesis and biological evaluation of 1H-indazole derivatives as InhA inhibitors and anticancer agents
- 20 February 2026
- Published by Springer Nature in Journal of Chemical Sciences
- Vol. 138 (1) , 14
Design, synthesis and biological evaluation of 1H-indazole derivatives as InhA inhibitors and anticancer agents
- 12 November 2025
- Published by Wiley in Journal of Applied Toxicology
- Vol. 46 (5) , 1654-1666
Synthesis and Toxicological Evaluation of N‐Nitroso Vildagliptin Amide Impurity in BALB 3T3 Clone Cells
Nitrosamine impurities in pharmaceuticals have become a significant regulatory concern because of their established carcinogenic and genotoxic potential. N‐nitroso vildagliptin amide impurity (NNVI), associated with the antidiabetic drug vildagliptin, raises potential safety concerns, yet its biological toxicity remains inadequately explored. To address this gap in our study, we synthesized and characterized NNVI and evaluated its cytotoxic, oxidative, and genotoxic effects using BALB 3T3 cell lines, within the context of the US FDA's acceptable daily intake (ADI) limit for NNVI. NNVI was synthesized under mild acidic conditions via nitrosation of the vildagliptin amide intermediate and confirmed structurally using NMR, IR, and mass spectrometry. BALB 3T3 cells were treated with NNVI at concentrations ranging from 5 to 125 ppm. Cytotoxicity was assessed with the MTT assay, whereas oxidative stress was measured via levels of superoxide dismutase (SOD), catalase (CAT), malondialdehyde (MDA), nitric oxide synthases (iNOS), reduced glutathione (GSH), and Nrf2. Genotoxicity was determined through the alkaline comet assay. The results showed a dose‐dependent decrease in cell viability, with significant cytotoxicity observed at concentrations ≥ 50 ppm. Oxidative stress markers indicated adaptive antioxidant responses at lower concentrations (5–25 ppm), but higher concentrations caused oxidative imbalance, antioxidant depletion, and increased lipid peroxidation. Genotoxic effects were evident at 100 ppm, with increased DNA tail intensity. These findings confirm that NNVI presents a toxicological risk at concentrations above regulatory limits. The study underscores the importance of strict impurity control in pharmaceutical formulations and contributes to the wider effort of ensuring drug safety by limiting nitrosamine exposure to acceptable thresholds.
- 12 November 2025
- Published by Wiley in Journal of Applied Toxicology
- Vol. 46 (5) , 1654-1666
Synthesis and Toxicological Evaluation of N‐Nitroso Vildagliptin Amide Impurity in BALB 3T3 Clone Cells
Nitrosamine impurities in pharmaceuticals have become a significant regulatory concern because of their established carcinogenic and genotoxic potential. N‐nitroso vildagliptin amide impurity (NNVI), associated with the antidiabetic drug vildagliptin, raises potential safety concerns, yet its biological toxicity remains inadequately explored. To address this gap in our study, we synthesized and characterized NNVI and evaluated its cytotoxic, oxidative, and genotoxic effects using BALB 3T3 cell lines, within the context of the US FDA's acceptable daily intake (ADI) limit for NNVI. NNVI was synthesized under mild acidic conditions via nitrosation of the vildagliptin amide intermediate and confirmed structurally using NMR, IR, and mass spectrometry. BALB 3T3 cells were treated with NNVI at concentrations ranging from 5 to 125 ppm. Cytotoxicity was assessed with the MTT assay, whereas oxidative stress was measured via levels of superoxide dismutase (SOD), catalase (CAT), malondialdehyde (MDA), nitric oxide synthases (iNOS), reduced glutathione (GSH), and Nrf2. Genotoxicity was determined through the alkaline comet assay. The results showed a dose‐dependent decrease in cell viability, with significant cytotoxicity observed at concentrations ≥ 50 ppm. Oxidative stress markers indicated adaptive antioxidant responses at lower concentrations (5–25 ppm), but higher concentrations caused oxidative imbalance, antioxidant depletion, and increased lipid peroxidation. Genotoxic effects were evident at 100 ppm, with increased DNA tail intensity. These findings confirm that NNVI presents a toxicological risk at concentrations above regulatory limits. The study underscores the importance of strict impurity control in pharmaceutical formulations and contributes to the wider effort of ensuring drug safety by limiting nitrosamine exposure to acceptable thresholds.
- Open Access
- 7 July 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 241-253
QBD (QUALITY BY DESIGN) APPROACH: DEVELOPMENT AND VALIDATION OF AN RP-HPLC METHOD FOR ESTIMATING IMEGLIMIN HCL AND ITS KETONE IMPURITY
Objective: Quality by Design (QbD) is a structured approach that ensures consistently high-quality outcomes by following a systematic methodology. This study aimed to develop and validate a robust and reliable Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) method for the simultaneous quantification of Imeglimin hydrochloride (IMG) and its ketone impurity, Imeglimin Ketone Impurity (IKI), utilizing a Quality by Design (QbD) approach to ensure enhanced method precision, accuracy, and regulatory compliance. Methods: A risk-based strategy guided method development, employing the Agilent Zorbax Bonus RP (AZB-RP) column (25 cm×4.6 mm, 5.0 µm) under isocratic elution with a Mobile Phase (MP) of Trifluoroacetic acid (TFA) and Acetonitrile (ACN) (45:55 v/v). Chromatographic conditions included a flow rate of 0.45 ml/min, an injection volume of 10 µl**, and a column temperature of 30 °C. A Central Composite Design (CCD) was applied to study the influence of MP ratio and Flow Rate (FR) on Critical Analytical Parameters (CAPs) using Design Expert 13.0 software. Results: The method showed excellent linearity with R² = 0.9998 for imeglimin hydrochloride (80–120 ppm) and R² = 0.9994 for its ketone impurity (4–6 ppm) at 238 nm. The recovery was 100.02–100.78% for imeglimin hydrochloride and 99.98–100.02% for the impurity. The Limit of Detection (LOD) and Limit of Quantitation (LOQ) for the impurity were 0.23 ppm and 0.70 ppm, respectively. The Analysis of Variance (ANOVA) results confirmed the model’s significance and predictive ability, highlighting the method’s robustness and reliability for routine quality control applications. Conclusion: The QbD-based RP-HPLC method described here is accurate, precise, and robust for the simultaneous estimation of IMG and IKI and can be used for routine quality control.
- 7 July 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 241-253
Open AccessQBD (QUALITY BY DESIGN) APPROACH: DEVELOPMENT AND VALIDATION OF AN RP-HPLC METHOD FOR ESTIMATING IMEGLIMIN HCL AND ITS KETONE IMPURITY
Objective: Quality by Design (QbD) is a structured approach that ensures consistently high-quality outcomes by following a systematic methodology. This study aimed to develop and validate a robust and reliable Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) method for the simultaneous quantification of Imeglimin hydrochloride (IMG) and its ketone impurity, Imeglimin Ketone Impurity (IKI), utilizing a Quality by Design (QbD) approach to ensure enhanced method precision, accuracy, and regulatory compliance. Methods: A risk-based strategy guided method development, employing the Agilent Zorbax Bonus RP (AZB-RP) column (25 cm×4.6 mm, 5.0 µm) under isocratic elution with a Mobile Phase (MP) of Trifluoroacetic acid (TFA) and Acetonitrile (ACN) (45:55 v/v). Chromatographic conditions included a flow rate of 0.45 ml/min, an injection volume of 10 µl**, and a column temperature of 30 °C. A Central Composite Design (CCD) was applied to study the influence of MP ratio and Flow Rate (FR) on Critical Analytical Parameters (CAPs) using Design Expert 13.0 software. Results: The method showed excellent linearity with R² = 0.9998 for imeglimin hydrochloride (80–120 ppm) and R² = 0.9994 for its ketone impurity (4–6 ppm) at 238 nm. The recovery was 100.02–100.78% for imeglimin hydrochloride and 99.98–100.02% for the impurity. The Limit of Detection (LOD) and Limit of Quantitation (LOQ) for the impurity were 0.23 ppm and 0.70 ppm, respectively. The Analysis of Variance (ANOVA) results confirmed the model’s significance and predictive ability, highlighting the method’s robustness and reliability for routine quality control applications. Conclusion: The QbD-based RP-HPLC method described here is accurate, precise, and robust for the simultaneous estimation of IMG and IKI and can be used for routine quality control.
- 1 July 2025
- Published by Wiley in ChemistrySelect
- Vol. 10 (25)
Design, Synthesis, and Inhibitory Activity of Benzimidazole‐2‐thiol Derivatives on SHSY‐5Y Neuroblastoma Cancer Cell Line
Neuroblastoma, a prevalent childhood cancer, necessitates the design of more potent and more selective drugs. Benzimidazole derivatives are reported to possess significant anticancer activity in recent investigations. In this report, we designed, synthesized, and tested a new series of benzimidazole‐2‐thiol derivatives targeting the WD repeat‐containing protein 5 (WDR5), particularly its less‐studied WBM (WDR5 binding motif) binding site. 10 derivatives were prepared and characterized by IR, ¹H NMR, ¹ 3 C NMR, and LC–MS. In silico docking and ADMET profiling revealed good binding affinity, pharmacokinetics, and blood–brain barrier permeability. HS‐5G and HS‐5H of the synthesized compounds were found to possess high inhibitory activity against SH‐SY5Y neuroblastoma cells, and high cytotoxicity was reported at 48 h (IC₅₀ = 25 µM). Structure‐activity relationship (SAR) analysis implied the enhancement of activity by dichloro substitutions due to improved hydrophobic interactions and target binding. This research shows one of the earliest examples of benzimidazole‐2‐thiol derivatives that have been designed to inhibit the WBM site of WDR5. The integration of docking‐guided synthesis, favorable ADMET profiles, and compelling in vitro activity places HS‐5G and HS‐5H as prominent lead candidates for further investigation in neuroblastoma treatment.
- 1 July 2025
- Published by Wiley in ChemistrySelect
- Vol. 10 (25)
Design, Synthesis, and Inhibitory Activity of Benzimidazole‐2‐thiol Derivatives on SHSY‐5Y Neuroblastoma Cancer Cell Line
Neuroblastoma, a prevalent childhood cancer, necessitates the design of more potent and more selective drugs. Benzimidazole derivatives are reported to possess significant anticancer activity in recent investigations. In this report, we designed, synthesized, and tested a new series of benzimidazole‐2‐thiol derivatives targeting the WD repeat‐containing protein 5 (WDR5), particularly its less‐studied WBM (WDR5 binding motif) binding site. 10 derivatives were prepared and characterized by IR, ¹H NMR, ¹ 3 C NMR, and LC–MS. In silico docking and ADMET profiling revealed good binding affinity, pharmacokinetics, and blood–brain barrier permeability. HS‐5G and HS‐5H of the synthesized compounds were found to possess high inhibitory activity against SH‐SY5Y neuroblastoma cells, and high cytotoxicity was reported at 48 h (IC₅₀ = 25 µM). Structure‐activity relationship (SAR) analysis implied the enhancement of activity by dichloro substitutions due to improved hydrophobic interactions and target binding. This research shows one of the earliest examples of benzimidazole‐2‐thiol derivatives that have been designed to inhibit the WBM site of WDR5. The integration of docking‐guided synthesis, favorable ADMET profiles, and compelling in vitro activity places HS‐5G and HS‐5H as prominent lead candidates for further investigation in neuroblastoma treatment.
- Open Access
Optimization of Anthralin Microemulgel Targeted Delivery for Psoriasis and Acne
Background: Anthralin is known for its efficacy in treating psoriasis and acne, possessing poor solubility. Addressing these limitations, the present study endeavors to develop a microemulgel formulation of anthralin aimed at enhancing solubility. Method: The solubility study was performed in various solvents. An o/w (oil-in-water) emulsion was formed using the water titration method, which was optimized by statistical experimental design half-run CCD. The final optimized batch was evaluated for physicochemical and in vitro properties Result: The final optimized batch showed a particle size (PS) of 417 nm, −25.2 mV zeta potential (ZP) and pH 5.8, which remained stable upon centrifugation, heating–cooling and freeze–thawing cycle. Furthermore, microemulsion with Carbopol 943 5% w/v was selected as the gel base for the formation of microemulgel characterized by PS, ZP, pH, and viscosity of 230 nm, −50.6 mV, 6.9 and 14,200 cps, respectively, that ensured it a high enough stability. In silico molecular docking between ligand and protein provides the binding energies validating the interaction. Hence, the in silico study was performed for psoriasis and P. acne proteins. An in vitro antibacterial activity study on Propionibacterium revealed a significant efficiency of the formulation and MTT assay using L929 cell line in the presence of the drug-loaded microemulgel indicated an inhibition of growth proving that formulation has anti-psoriatic activity. Conclusions: Combination therapy with Clindamycin might improve efficacy while reducing antibiotic resistance risks.
Open AccessOptimization of Anthralin Microemulgel Targeted Delivery for Psoriasis and Acne
Background: Anthralin is known for its efficacy in treating psoriasis and acne, possessing poor solubility. Addressing these limitations, the present study endeavors to develop a microemulgel formulation of anthralin aimed at enhancing solubility. Method: The solubility study was performed in various solvents. An o/w (oil-in-water) emulsion was formed using the water titration method, which was optimized by statistical experimental design half-run CCD. The final optimized batch was evaluated for physicochemical and in vitro properties Result: The final optimized batch showed a particle size (PS) of 417 nm, −25.2 mV zeta potential (ZP) and pH 5.8, which remained stable upon centrifugation, heating–cooling and freeze–thawing cycle. Furthermore, microemulsion with Carbopol 943 5% w/v was selected as the gel base for the formation of microemulgel characterized by PS, ZP, pH, and viscosity of 230 nm, −50.6 mV, 6.9 and 14,200 cps, respectively, that ensured it a high enough stability. In silico molecular docking between ligand and protein provides the binding energies validating the interaction. Hence, the in silico study was performed for psoriasis and P. acne proteins. An in vitro antibacterial activity study on Propionibacterium revealed a significant efficiency of the formulation and MTT assay using L929 cell line in the presence of the drug-loaded microemulgel indicated an inhibition of growth proving that formulation has anti-psoriatic activity. Conclusions: Combination therapy with Clindamycin might improve efficacy while reducing antibiotic resistance risks.
A Review on Carbazole and Its Derivatives as Anticancer Agents From 2013 to 2024
Carbazole, a natural alkaloid, has been recognized as an effective anticancer agent for over 40 years. However, only a limited number of carbazole‐based compounds have received FDA approval for cancer treatment. Current cancer therapies are often associated with significant side effects, causing physical, emotional, and financial burdens for patients. Additionally, despite advancements, cancer prevention and treatment remain challenging due to suboptimal clinical outcomes. The development of new drugs is crucial for achieving safer and more effective cancer therapies. This review focuses on various carbazole derivatives and hybrid composites, highlighting their interactions with distinct receptors and their mechanisms of anticancer action, along with a general structure–activity relationship (SAR). It also emphasizes carbazole‐based compounds employed in chemoprevention, which aim to delay or prevent malignant progression. By covering carbazole derivatives and their anticancer potential from 2013 to the present, along with their current clinical status, this study offers valuable insights and updates for researchers in the field.
A Review on Carbazole and Its Derivatives as Anticancer Agents From 2013 to 2024
Carbazole, a natural alkaloid, has been recognized as an effective anticancer agent for over 40 years. However, only a limited number of carbazole‐based compounds have received FDA approval for cancer treatment. Current cancer therapies are often associated with significant side effects, causing physical, emotional, and financial burdens for patients. Additionally, despite advancements, cancer prevention and treatment remain challenging due to suboptimal clinical outcomes. The development of new drugs is crucial for achieving safer and more effective cancer therapies. This review focuses on various carbazole derivatives and hybrid composites, highlighting their interactions with distinct receptors and their mechanisms of anticancer action, along with a general structure–activity relationship (SAR). It also emphasizes carbazole‐based compounds employed in chemoprevention, which aim to delay or prevent malignant progression. By covering carbazole derivatives and their anticancer potential from 2013 to the present, along with their current clinical status, this study offers valuable insights and updates for researchers in the field.
- 1 December 2024
- Published by Bentham Science Publishers Ltd. in Medicinal Chemistry
- Vol. 20 (10) , 957-968
Design, Synthesis and Evaluation of Antifungal Activity of Pyrazoleacetamide Derivatives
Background: Fungal infections have posed a big challenge in the management of their treatment. Due to the resistance and toxicity of existing drug molecules in the light of pandemic infections, like COVID-19, there is an urgent need to find newer derivatives of active molecules, which can be effective in fungal infections. Objective: In the present study, we aimed to design pyrazole derivatives using molecular modeling studies against target 1EA1 and synthesize 10 molecules of pyrazole derivatives using a multi-step synthesis approach. Methods: Designed pyrazole derivatives were synthesized by conventional organic methods. The newly synthesized pyrazole molecules were characterized by using FT-IR, 1HNMR, 13CNMR, and LC-MS techniques. Molecular docking studies were also performed. The antifungal activity of newly synthesized compounds was assessed in vitro against Candida albicans and Aspergillus niger using the well plate method. Results: Two of the compounds, OK-7 and OK-8, have been found to show significant docking interaction with target protein 1EA1. These two compounds have also been found to show significant anti-fungal activity against Candida albicans and Aspergillus nigra when compared to the standard fluconazole. The Minimum Inhibitory Concentration (MIC) value of these two compounds has been found to be 50 μg/ml. Conclusion: Pyrazole derivatives with -CH3, CH3O-, and -CN groups have been found to be active against tested fungi and can be further explored for their potential as promising anti-fungal agents for applications in the field of medicinal chemistry.
- 1 December 2024
- Published by Bentham Science Publishers Ltd. in Medicinal Chemistry
- Vol. 20 (10) , 957-968
Design, Synthesis and Evaluation of Antifungal Activity of Pyrazoleacetamide Derivatives
Background: Fungal infections have posed a big challenge in the management of their treatment. Due to the resistance and toxicity of existing drug molecules in the light of pandemic infections, like COVID-19, there is an urgent need to find newer derivatives of active molecules, which can be effective in fungal infections. Objective: In the present study, we aimed to design pyrazole derivatives using molecular modeling studies against target 1EA1 and synthesize 10 molecules of pyrazole derivatives using a multi-step synthesis approach. Methods: Designed pyrazole derivatives were synthesized by conventional organic methods. The newly synthesized pyrazole molecules were characterized by using FT-IR, 1HNMR, 13CNMR, and LC-MS techniques. Molecular docking studies were also performed. The antifungal activity of newly synthesized compounds was assessed in vitro against Candida albicans and Aspergillus niger using the well plate method. Results: Two of the compounds, OK-7 and OK-8, have been found to show significant docking interaction with target protein 1EA1. These two compounds have also been found to show significant anti-fungal activity against Candida albicans and Aspergillus nigra when compared to the standard fluconazole. The Minimum Inhibitory Concentration (MIC) value of these two compounds has been found to be 50 μg/ml. Conclusion: Pyrazole derivatives with -CH3, CH3O-, and -CN groups have been found to be active against tested fungi and can be further explored for their potential as promising anti-fungal agents for applications in the field of medicinal chemistry.